T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Guido Ghilardi(Hospital of the University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Carl H. June(University of Pennsylvania), Irina Kulikovskaya(University of Pennsylvania), Elise A. Chong(Hospital of the University of Pennsylvania), Stefan K. Barta(University of Pennsylvania), Adam D. Cohen(Penn Center for AIDS Research), Adam Waxman(UPMC Hillman Cancer Center), Jennifer J.D. Morrissette(University of Pennsylvania), Edward A. Stadtmauer(University of Pennsylvania), Bruce L. Levine(University of Pennsylvania), Alfred L. Garfall(University of Pennsylvania), Joseph A. Fraietta(University of Pennsylvania), Jaryse Harris(Hospital of the University of Pennsylvania), Emeline R. Chong(Hospital of the University of Pennsylvania), James N. Gerson(UPMC Hillman Cancer Center), Vivianna M. Van Deerlin(Hospital of the University of Pennsylvania), Dan T. Vogl(University of Pennsylvania), Daniel J. Landsburg(University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), Eugenio Fardella(Hospital of the University of Pennsylvania), David L. Porter(Chapman University), Gabriel C. Caponetti(Hospital of the University of Pennsylvania), Stephen J. Schuster(Hospital of the University of Pennsylvania), Raymone Pajarillo(Hospital of the University of Pennsylvania), Sunita D. Nasta(University of Pennsylvania), Noelle V. Frey(Hospital of the University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), David Lieberman(University of Pennsylvania), Sandra P. Susanibar-Adaniya(Hospital of the University of Pennsylvania), Vrutti Patel(Hospital of the University of Pennsylvania), Jakub Svoboda(UPMC Hillman Cancer Center)
Cited by 254
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions
|Nature Genetics|2010|608